The Pharmaceutical Society of Great Britain P a l m e r lop nome for physiology and pharmacology apparatus Known and used in physiology and pharmacology laboratories all over the world, C. F. Palmer equipment has a long-standing reputation for quality, reliability and precision. New products are continually under development, and as a member of the Baird &Tatlock Group, C. F. Palmer have extensive research and development facilities at their disposal. Palmer equipment is now available on improved deliveries. For a revised delivery schedule, or to order your new catalogue, write to the address below. Palmer kymographs such as this are in service in labora- Continuous injector. This unit, which can be used with all sizes of record-type tories all over the world, providing smoked paper records syringes, automatically controls injection rates. A range of motor speeds is of muscle and tissue movement, or through a manometer, available giving emptying rates of 10 mins, to 480 rrins. per inch, of blood pressure. A 6-gear motor gives paper speeds from Square-Wave Stim ulator. Pro vines a square-wave output of independently •1mm to 10mm per second. A.C. time-clock and s gnal variable pulse r?te (1/20-100 p.p.s.), ou1*«. width (10 microsec. to 103 millisec.) markers, and the Starling ventilation pump are fitted. end :nt«nsKy. Fuise rate is controKaM* ether in steps or continuously. C. F. Palmer (London) Lt«5. <2/1$ C-neKsie Hu., Tne Hyde, Colindale, London, IM.W.9 Telephone: 01 -205 5432 Member cf '.he Baird & Tatlock Division of Tarmac Derby Limited C P .1 /C Journal of Pharmacy and Pharmacology Published by T h e P harmaceutical S o c ie t y o f G r e a t B r i t a i n 17 Bloomsbury Square, London, W.C.l. Telephone: 01-405 8967 Volume 21 Number 8 August 1969 Editor: George Brownlee, D.Sc., Ph.D., F.P.S. Assistant Editor: J. R. Fowler, B.Pharm., F.P.S Editorial Board: H. S. Bean, W. C. Bowman, H. Burlinson, J. E. Carless, F. Fish. G. E. Foster, F. Hartley, E. F. Hersant, C. A. Johnson, K. A. Lees, A. D. Macdonald, A. McCoubrey, D. W. Mathieson, M. J. Rand, G. F. Somers, J. B. Stenlake, G. B. West, R. T. Williams, Secretary. D. F. Lewis. Notice to Contributors T ables (for each copy of the text) should be typed on separate sheets, their headings should T h e J o u r n a l o f P h a r m a c y a n d P h a r m a ­ describe their content and they should be c o l o g y reviews and reports original research in understandable without reference to the text. those sciences which contribute to the develop­ They should not be ruled. ment and evaluation of medicinal substances, covering inter alia biochemistry, chemistry, Illustrations. Should be kept to the mini­ microbiology, pharmaceutics, pharmacognosy mum number necessary to the proper under­ and pharmacology. Short papers of immediate standing of the subject matter. Two of each interest are published as ‘Letters to the Editor.’ are required, one prepared as described below the other a photo copy suitable for submission Original research papers or review articles are to a referee. Line illustrations such as graphs accepted on the understanding that they are sub­ or apparatus diagrams should be clearly and ject to editorial revision and that their content boldly drawn in Indian ink on tracing cloth or has not been published in whole or in part paper, white paper, faintly blue-lined graph elsewhere. paper or Bristol board. The initial dimensions should be chosen to allow for a reduction to at Text. Authors should consult a c u r r e n t least one-half and not more than one-quarter of issue of the Journal and conform to the typo­ the original size. (Most illustrations in the graphical conventions, use of headings, lay-out Journal are 2-4 inches, in width.) Kymograph of tables, and citation of references. Texts records and photographs should be selected to must be typewritten in double spacing on sheets allow for reduction to a similar extent. Letter­ not larger than 9 13 inches (22 32 cm) x x ing and numbering should be inserted lightly with a li inch (3 cm) margin. The top copy and clearly in pencil. Curves based on experi­ and one carbon copy should be sent. The mental data should carry clear and bold name(s) of the contributor(s), the name and indications of the experimentally determined address of the laboratory where the work was points, which should be marked by using, done, and a shortened title (not more than a preferably, circles, crosses, triangles or squares. total of 50 letters and spaces) should accom­ Legends for illustrations should be typed on pany the typescript. The presentation adopted separate sheets of paper and appended to the should be that best suited to the clear exposition typescript of the paper or to the individual of the subject matter. A summary should be figures. The author’s name, the title of the included, giving results and conclusions in the paper and the number of the figure should be form of an abstract suitable for use as such by written lightly in pencil on the back of each abstracting journals. illustration. The approximate position of each illustration should be marked in the text. References. References s iould be arranged to the h a r v a r d system. In the text the R eprints. 50 reprints are supplied free of surname of the author(s) and the date of charge to the author. A further 10 reprints publication are given thus: Lewis & Train are supplied free to each co-author. Additional (1965) described . .. or ___ has been described reprints may be purchased. (Lewis & Train, 1965). The list of references is in alphabetical order of first authors and each Copyright reference is arranged as follows: L e w is , C. J. & T r a i n , D. (1965). J. Pharm. Pharmac., 17, © 1969 by the Journal of Pharmacy and 33-41. The title of publication is underlined Pharmacology. All rights of reproduction are and abbreviated as in World List of Scientific reserved in all countries in respect of all articles, Periodicals (4th edn, 1963-1965 and supple­ papers, illustrations, etc. ments) and is followed by the volume number and first and last page numbers. References to Annual subscription (including postage) £9, books should be as follows: G o o d m a n , L. S. & (LJ.S.A. $25). Single copies £1, (U.S.A. $3). G i l m a n , A. (1965). The Pharmacological Basis of Therapeutics, 3rd edn, p. 464, London: Claims for missing copies cannot be considered Collier-Macmillan. unless received within 3 months of publication. iv Journal of Pharmacy and Pharmacology August, 1969 d e l i v e r e d to your bench q u i c k l y Hundreds of different products in the complete Difco range are kept in stock ready to be on your bench without delay. We shall always be pleased to obtain other items specially to order. Speed, convenience, reliability . and remember that Difco offer the only c o m p le te line of culture media available in U.K. Please send for the latest literature concerning your special interests. la b o r a t o r y s e r v i c e BAIRD & TATLOCK (LONDON) LTD., CHADWELL HEATH, ESSEX, ENGLAND. Branches in London, Manchester, Birmingham and Glasgow. Member of Tarmac Derby Ltd T A 3 f D O . t 3 B J. Pharm. Pharmac., 1969, 21, 481-487 Received February 19, 1969 Simulation of the apparent effects of mebanazine on growth hormone by pair-feeding of control animals A. M. BARRETT Department o f Pharmacology, ICI Ltd., Pharmaceuticals Division, Alderley Park, Macclesfield, England The degree and duration of insulin hypoglycaemia was potentiated by chronic oral medication with mebanazine in rats. Hypo- physectomy alone increased sensitivity to insulin but did not abolish the potentiating effect of mebanazine. Chronic mebanazine treat­ ment (15 mg/kg/day) for 6 weeks markedly reduced weight gain, food and water consumption and pituitary growth hormone content, but the results were not significantly different from those in un­ medicated pair-fed controls. Similarly, immature rats treated with mebanazine had a significant reduction in the width of the tibial epiphysial cartilage but this was not different from that in pair-fed animals. After 18 h of fasting, acute administration of mebanazine had little effect on food consumption in the 2 h period following dosing but a significant effect over 24 h. In fed rats mebanazine in a single oral dose significantly reduced eating in the following 6 h. Treatment with mebanazine at 2-5 mg/kg for 15 days significantly reduced food intake but did not potentiate insulin hypoglycaemia. From the results it would appear that previous suggestions that mebanazine specifically interferes with growth hormone release are incorrect and the findings emphasize the importance of measuring food intake in experiments of long duration. Long-term administration of the monoamine oxidase inhibitor mebanazine to rats has been shown to potentiate the hypoglycaemic effects of both insulin and tolbut­ amide (Barrett, 1965). The results were compatible with the hypothesis that meban­ azine treatment interfered with the adrenergically mediated mechanisms for combating low circulating glucose levels. It was proposed that the pattern of insulin potentiation and hypotensive episodes during the clinical use of mebanazine (Wickstrom & Pettersson, 1964; Cooper & Keddie, 1964) might have a common origin.